Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
Background and objective: Best-value biological medicines may generate competition in the off-patent biologicals market, resulting in having more resources available to provide patients with access to necessary medicines while maintaining high-quality care. Belgium is a country known to have low bio...
Saved in:
Main Authors: | Yannick Vandenplas (Author), Steven Simoens (Author), Philippe Van Wilder (Author), Arnold G. Vulto (Author), Isabelle Huys (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study
by: Yannick Vandenplas, et al.
Published: (2022) -
Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis
by: Teresa Barcina Lacosta, et al.
Published: (2022) -
The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis
by: Yannick Vandenplas, et al.
Published: (2023) -
Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
by: Liese Barbier, et al.
Published: (2022) -
Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices
by: Liese Barbier, et al.
Published: (2021)